For patients with immunological or inflammatory unmet clinical needs

At Cell2B we focus in treating unmet immune and inflammatory diseases with our mesenchymal stem cell technology - ImmuneSafe®.
We have the European Medicine Agency’s clearance to start clinical trials for the treatment of steroid-refractory acute and severe Graft-versus-Host-Disease (GvHD).
Orphan designation has been granted in Europe. An early clinical study of the technology showed that it was safe in six patients suffering from GvHD.


ImmuneSafe® is composed of mesenchymal cells (MSC) expanded ex-vivo in xeno-free media. We isolate our MSC from the mononuclear cell fraction of the bone marrow of healthy donors using an automated system. These cells are then seeded in a Cell2B’s proprietary extracellular matrix platform, in xeno-free media. The result is a unique cell product with a distinct potency profile.


The current cost of treatment for immune and inflammatory responses exceeds €80 Billion per year worldwide. More than half of this amount is associated with medical procedures, chronic immunosuppressive or anti-inflammatory therapy, and hospitalization due to complications resulting from the chronic use of these drugs. The market for immunosuppressants – the current standard of care – in Europe is estimated to grow from €2 Billion in 2012 to €2.8 B in 2017 at a compound annual growth rate of 6.1%.
  Contact Name: Daniela Couto

Cell2B - Advanced Therapeutics S.A.
Biocant Park Núcleo 04 Lote 4A
3060-197 Cantanhede, Portugal

Phone: +351 231 410 906

Share |